Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...

When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...

The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities. A research team from ...

Thank you for your article on antisense 1 and for letting us know that the subject is very much alive. Although antisense is an "RNA therapeutic" in that the target is mRNA, actually in almost all ...

The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins -- yet it exists in large quantities. A research team has ...

An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...

PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the ...

BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q3z4pf/pharmasphere) has announced the addition of the "PharmaSphere ...

GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory RNA-targeting therapeutics in neurodegenerative and kidney disease indications.